Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum
The Readout Loud
00:00
Carta's Engineered and K Cell Therapies Induce Complete Remissions
Yameg: A company called ancarda is developing therapies that start with natural killer cells, often referred to as n k cells. yameg: Preliminary results from two studies in which its engineered and k cel treatments induce complete responses in patients with advanced forms of blood cancer. Yameg: Both the companies engineered and caeltheripes were well tolerated by patients; no serious immune system or neura al side effects.
Transcript
Play full episode
